FDA Advisory Panel Deals Blow to Phillip Morris International’s iQOS Device


Not all the comments made by the advisory group were negative, offering a chance the device could still earn its modified risk classification, a move Phillips Morris International, Inc. has been working toward with the decline of traditional cigarette sales and the FDA’s recent policy shift toward nicotine addiction and seeking safer alternatives to smoking and traditional tobacco products. A final decision from the FDA is expected this year, though no exact timeframe is available.

If approved, Phillip Morris International, Inc.’s partner Altria Group, Inc. would be able to sell and market iQOS within the U.S. with modified-risk claims.